Literature DB >> 3894122

Recognition of human insulin and proinsulin by monoclonal antibodies.

M J Storch, K G Petersen, T Licht, L Kerp.   

Abstract

High-affinity monoclonal antibodies (MAB) were obtained from lymph node cell fusions. Affinities ranging from 0.8 X 10(9) L/M to 5.2 X 10(9) L/M were calculated from binding studies with monoiodinated human, bovine, and porcine insulins and human proinsulin. Two monoclonal antibodies were specific for human insulin, recognizing an epitope involving the amino acid B-30 (Thr). Another two monoclonal antibodies were bound to the C-terminal end of the B-chain near B-30. The B-chain-specific monoclonal antibodies did not bind human proinsulin. One monoclonal antibody recognized the A-chain loop in the positions A-8 to A-10. This antibody bound also to human proinsulin. It was concluded that the A-chain loop is exposed on the surface of proinsulin, while the C-terminal B-chain is not available for binding. The study shows that monoclonal antibodies can be used to characterize structures of insulin and proinsulin. In contrast to x-ray studies, the molecules can be used at low concentrations in soluble form. It is suggested to use monoclonal antibodies for the screening of atypical insulins in the serum of diabetic patients and for the further refinement of insulin and proinsulin measurements.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894122     DOI: 10.2337/diab.34.8.808

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  Islet amyloid polypeptide immunoreactivity in the human fetal pancreas.

Authors:  P A In 't Veld; F Zhang; O D Madsen; G Klöppel
Journal:  Diabetologia       Date:  1992-03       Impact factor: 10.122

Review 2.  Applications of immunogold and lectin-gold labeling in tumor research and diagnosis.

Authors:  J Roth; C Zuber; P Komminoth; T Sata; W P Li; P U Heitz
Journal:  Histochem Cell Biol       Date:  1996-07       Impact factor: 4.304

3.  Antigenicity of the carboxyl terminus of insulin: isolation of human insulin-specific monoclonal antibodies.

Authors:  I H Mirza; T J Wilkin
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

4.  Inositol 1,4,5-trisphosphate receptor subtype 3 in pancreatic islet cell secretory granules revisited.

Authors:  M Ravazzola; P A Halban; L Orci
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

5.  Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.

Authors:  S J Mandriota; L Jussila; M Jeltsch; A Compagni; D Baetens; R Prevo; S Banerji; J Huarte; R Montesano; D G Jackson; L Orci; K Alitalo; G Christofori; M S Pepper
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

6.  Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3.

Authors:  Xiaorong Zhu; Lelio Orci; Raymond Carroll; Christina Norrbom; Mariella Ravazzola; Donald F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

7.  Endocrine pancreatic tumors in MSV-SV40 large T transgenic mice.

Authors:  W Götz; C Schucht; J Roth; F Theuring; R Herken
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

8.  Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness.

Authors:  D M Harlan; H Hengartner; M L Huang; Y H Kang; R Abe; R W Moreadith; H Pircher; G S Gray; P S Ohashi; G J Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  Topographic abnormalities of proinsulin to insulin conversion in functioning human insulinomas. Comparison of immunoelectron microscopic and clinical data.

Authors:  J Roth; P Komminoth; P U Heitz
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.